子宮内膜症治療薬の世界市場

子宮内膜症治療薬の世界市場は2030年までに36億米ドルに達する見込み

2023年に30億米ドルと推定される子宮内膜症治療薬の世界市場は、分析期間2023-2030年にCAGR 3.0%で成長し、2030年には36億米ドルに達すると予測されます。本レポートで分析したセグメントの1つであるホルモン療法は、CAGR 3.3%を記録し、分析期間終了時には22億米ドルに達すると予測されます。鎮痛剤セグメントの成長率は、分析期間中CAGR 2.6％と推定されます。

米国市場は7億9,470万米ドルと推定、中国はCAGR 2.9％で成長予測

米国の子宮内膜症治療薬市場は、2023年に7億9,470万米ドルと推定されます。世界第2位の経済大国である中国は、2030年までに5億8,010万米ドルの市場規模に達すると予測され、分析期間2023-2030年のCAGRは2.9%です。その他の注目すべき地域別市場としては、日本とカナダがあり、分析期間中のCAGRはそれぞれ2.8%と2.6%と予測されています。欧州では、ドイツがCAGR約3.0％で成長すると予測されています。

子宮内膜症治療薬-主要動向と促進要因

子宮内膜症は、子宮外の子宮内膜様組織の増殖を特徴とする慢性婦人科疾患で、激しい痛み、不正出血、不妊症の原因となります。この疾患の治療には、外科的介入や薬理学的治療など、多面的なアプローチが必要となることが多いです。子宮内膜症治療薬の主な目的は、疼痛を緩和し、炎症を抑え、この疾患に伴うホルモンバランスの乱れを管理することです。最も一般的に処方される薬剤には、鎮痛のための非ステロイド性抗炎症薬（NSAIDs）、月経周期を調節するためのホルモン避妊薬、エストロゲン濃度を下げ子宮内膜組織を縮小させるためのゴナドトロピン放出ホルモン（GnRH）作動薬および拮抗薬があります。その他の治療法としては、プロゲステロンというホルモンを模倣して子宮内膜の増殖を抑えるプロゲスチンや、エストロゲンの産生を抑えるアロマターゼ阻害薬があります。これらの治療戦略は、子宮内膜症に苦しむ女性の症状を緩和し、生活の質を向上させる上で非常に重要です。

いくつかの動向が、子宮内膜症治療薬の開発と治療の状況を形成しています。重要な動向のひとつは、個人の遺伝的、ホルモン的、症状的プロファイルに合わせた治療を行う個別化医療への注目の高まりです。このアプローチは、研究者が子宮内膜症の根本的なメカニズムを解明し、より高い有効性とより少ない副作用を約束する標的療法の開発につながるにつれて、支持を集めています。さらに、長期のホルモン療法に伴う副作用や禁忌のため、非ホルモン療法への関心が高まっています。この分野の技術革新には、子宮内膜症に特異的な炎症経路や疼痛受容体を標的とする薬剤が含まれます。さらに、分子イメージングやバイオマーカー同定などの診断ツールの進歩により、疾患の早期発見とモニタリングが改善され、よりタイムリーで効果的な介入が可能となっています。

子宮内膜症治療薬市場の成長は、いくつかの要因によってもたらされます。創薬および薬剤開発における技術の進歩により、安全性と有効性のプロファイルが改善された新規治療薬の創出が可能になっています。子宮内膜症の有病率の増加は、意識の高まりと診断率の向上と相まって、治療を必要とする患者集団を拡大しています。さらに、個別化医療と精密医療へのシフトは、各患者の固有のニーズに対応するカスタマイズされた治療計画の開発を促進し、治療成果を高めています。非ホルモン治療オプションへの需要も、ホルモン療法に耐えられない患者に対する解決策を提供するため、市場成長を後押ししています。さらに、製薬企業による研究開発への多額の投資と、女性の健康に対する政府の支援策や資金援助が、新しく効果的な子宮内膜症治療の導入を加速しています。このような複合的な要因が子宮内膜症治療薬市場の力強い成長を促し、世界中の罹患女性の緊急ニーズに応えています。

調査対象企業の例（全38件）

• AbbVie Inc.
• Astellas Pharma Inc.
• AstraZeneca Plc
• Bayer AG
• Debiopharm Group
• Evotec AG
• Kissei Pharmaceutical Co. Ltd.
• Neurocrine Biosciences Inc.
• ObsEva SA
• Pfizer Inc.
• Repros Therapeutics Inc.
• Takeda Pharmaceutical Company Limited
• ValiRx plc

目次

第1章 調査手法

第2章 エグゼクティブサマリー

• 市場概要
• 主要企業
• 市場動向と促進要因
• 世界市場の見通し

第3章 市場分析

• 米国
• カナダ
• 日本
• 中国
• 欧州
• フランス
• ドイツ
• イタリア
• 英国
• その他欧州
• アジア太平洋
• 世界のその他の地域

第4章 競合

Global Endometriosis Drugs Market to Reach US$3.6 Billion by 2030

The global market for Endometriosis Drugs estimated at US$3.0 Billion in the year 2023, is expected to reach US$3.6 Billion by 2030, growing at a CAGR of 3.0% over the analysis period 2023-2030. Hormone Therapy, one of the segments analyzed in the report, is expected to record a 3.3% CAGR and reach US$2.2 Billion by the end of the analysis period. Growth in the Analgesics segment is estimated at 2.6% CAGR over the analysis period.

The U.S. Market is Estimated at US$794.7 Million While China is Forecast to Grow at 2.9% CAGR

The Endometriosis Drugs market in the U.S. is estimated at US$794.7 Million in the year 2023. China, the world's second largest economy, is forecast to reach a projected market size of US$580.1 Million by the year 2030 trailing a CAGR of 2.9% over the analysis period 2023-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 2.8% and 2.6% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 3.0% CAGR.

Endometriosis Drugs - Key Trends and Drivers

Endometriosis is a chronic gynecological condition characterized by the growth of endometrial-like tissue outside the uterus, causing severe pain, irregular bleeding, and infertility. Managing this condition often requires a multifaceted approach, including surgical intervention and pharmacological treatment. Endometriosis drugs primarily aim to alleviate pain, reduce inflammation, and manage the hormonal imbalances associated with the disease. The most commonly prescribed medications include nonsteroidal anti-inflammatory drugs (NSAIDs) for pain relief, hormonal contraceptives to regulate menstrual cycles, and gonadotropin-releasing hormone (GnRH) agonists and antagonists to lower estrogen levels and shrink endometrial tissue. Other treatments involve progestins, which mimic the hormone progesterone to suppress endometrial growth, and aromatase inhibitors, which reduce estrogen production. These therapeutic strategies are critical in providing symptom relief and improving the quality of life for women suffering from endometriosis.

Several trends are shaping the landscape of endometriosis drug development and treatment. One significant trend is the growing focus on personalized medicine, where treatments are tailored to the individual’s specific genetic, hormonal, and symptomatic profile. This approach is gaining traction as researchers uncover more about the underlying mechanisms of endometriosis, leading to the development of targeted therapies that promise greater efficacy and fewer side effects. Additionally, there is an increasing interest in non-hormonal treatments due to the side effects and contraindications associated with long-term hormonal therapy. Innovations in this area include drugs that target the inflammatory pathways and pain receptors specific to endometriosis. Furthermore, advancements in diagnostic tools, such as molecular imaging and biomarker identification, are improving early detection and monitoring of the disease, allowing for more timely and effective intervention.

The growth in the endometriosis drugs market is driven by several factors. Technological advancements in drug discovery and development are enabling the creation of novel therapies with improved safety and efficacy profiles. The increasing prevalence of endometriosis, coupled with heightened awareness and better diagnosis rates, is expanding the patient population requiring treatment. Additionally, the shift towards personalized and precision medicine is fostering the development of customized treatment plans that cater to the unique needs of each patient, enhancing therapeutic outcomes. The demand for non-hormonal treatment options is also propelling market growth, as these alternatives offer solutions for patients who cannot tolerate hormonal therapies. Furthermore, substantial investments in research and development by pharmaceutical companies, along with supportive government initiatives and funding for women's health, are accelerating the introduction of new and effective endometriosis treatments. These combined factors are driving robust growth in the endometriosis drugs market, meeting the urgent needs of affected women worldwide.

Select Competitors (Total 38 Featured) -

• AbbVie Inc.
• Astellas Pharma Inc.
• AstraZeneca Plc
• Bayer AG
• Debiopharm Group
• Evotec AG
• Kissei Pharmaceutical Co. Ltd.
• Neurocrine Biosciences Inc.
• ObsEva SA
• Pfizer Inc.
• Repros Therapeutics Inc.
• Takeda Pharmaceutical Company Limited
• ValiRx plc

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

• 1. MARKET OVERVIEW
  • Influencer Market Insights
  • Global Economic Update
  • Endometriosis Drugs - Global Key Competitors Percentage Market Share in 2024 (E)
  • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2024 (E)
• 2. FOCUS ON SELECT PLAYERS
• 3. MARKET TRENDS & DRIVERS
  • Increasing Focus on Personalized Medicine Propels Growth in Endometriosis Treatments
  • Innovations in Non-Hormonal Therapies Expand Addressable Market Opportunity
  • Advances in Diagnostic Tools Strengthen Business Case for Early Detection and Treatment
  • Rising Prevalence of Endometriosis Drives Demand for Effective Drugs
  • Advancements in Drug Discovery Accelerate Development of Novel Therapies
  • Improved Awareness and Diagnosis Rates Spur Growth in Endometriosis Drug Market
  • Demand for Non-Hormonal Treatment Options Generates Opportunities for New Therapies
  • Development of Targeted Therapies Enhance Treatment Efficacy and Safety
  • Impact of Personalized and Precision Medicine on Treatment Plans and Patient Outcomes
  • Consumer Demand for Effective and Safer Treatment Options Spurs Market Demand
  • Advancements in Molecular Imaging and Biomarker Identification Enhance Disease Monitoring
  • Shift towards Tailored Treatment Plans Throws the Spotlight on Patient-Centric Care
  • Challenges in Long-Term Hormonal Therapy Drive Interest in Alternative Treatments
• 4. GLOBAL MARKET PERSPECTIVE
  • TABLE 1: World Endometriosis Drugs Market Analysis of Annual Sales in US$ Million for Years 2014 through 2030
  • TABLE 2: World Recent Past, Current & Future Analysis for Endometriosis Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
  • TABLE 3: World Historic Review for Endometriosis Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 4: World 16-Year Perspective for Endometriosis Drugs by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets for Years 2014, 2024 & 2030
  • TABLE 5: World Recent Past, Current & Future Analysis for Hormone therapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
  • TABLE 6: World Historic Review for Hormone therapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 7: World 16-Year Perspective for Hormone therapy by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030
  • TABLE 8: World Recent Past, Current & Future Analysis for Analgesics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
  • TABLE 9: World Historic Review for Analgesics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 10: World 16-Year Perspective for Analgesics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030

III. MARKET ANALYSIS

• UNITED STATES
  • Endometriosis Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2024 (E)
  • TABLE 11: USA Recent Past, Current & Future Analysis for Endometriosis Drugs by Product Type - Hormone therapy and Analgesics - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 12: USA Historic Review for Endometriosis Drugs by Product Type - Hormone therapy and Analgesics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 13: USA 16-Year Perspective for Endometriosis Drugs by Product Type - Percentage Breakdown of Value Sales for Hormone therapy and Analgesics for the Years 2014, 2024 & 2030
• CANADA
  • TABLE 14: Canada Recent Past, Current & Future Analysis for Endometriosis Drugs by Product Type - Hormone therapy and Analgesics - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 15: Canada Historic Review for Endometriosis Drugs by Product Type - Hormone therapy and Analgesics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 16: Canada 16-Year Perspective for Endometriosis Drugs by Product Type - Percentage Breakdown of Value Sales for Hormone therapy and Analgesics for the Years 2014, 2024 & 2030
• JAPAN
  • Endometriosis Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2024 (E)
  • TABLE 17: Japan Recent Past, Current & Future Analysis for Endometriosis Drugs by Product Type - Hormone therapy and Analgesics - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 18: Japan Historic Review for Endometriosis Drugs by Product Type - Hormone therapy and Analgesics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 19: Japan 16-Year Perspective for Endometriosis Drugs by Product Type - Percentage Breakdown of Value Sales for Hormone therapy and Analgesics for the Years 2014, 2024 & 2030
• CHINA
  • Endometriosis Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2024 (E)
  • TABLE 20: China Recent Past, Current & Future Analysis for Endometriosis Drugs by Product Type - Hormone therapy and Analgesics - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 21: China Historic Review for Endometriosis Drugs by Product Type - Hormone therapy and Analgesics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 22: China 16-Year Perspective for Endometriosis Drugs by Product Type - Percentage Breakdown of Value Sales for Hormone therapy and Analgesics for the Years 2014, 2024 & 2030
• EUROPE
  • Endometriosis Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2024 (E)
  • TABLE 23: Europe Recent Past, Current & Future Analysis for Endometriosis Drugs by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
  • TABLE 24: Europe Historic Review for Endometriosis Drugs by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 25: Europe 16-Year Perspective for Endometriosis Drugs by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK and Rest of Europe Markets for Years 2014, 2024 & 2030
  • TABLE 26: Europe Recent Past, Current & Future Analysis for Endometriosis Drugs by Product Type - Hormone therapy and Analgesics - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 27: Europe Historic Review for Endometriosis Drugs by Product Type - Hormone therapy and Analgesics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 28: Europe 16-Year Perspective for Endometriosis Drugs by Product Type - Percentage Breakdown of Value Sales for Hormone therapy and Analgesics for the Years 2014, 2024 & 2030
• FRANCE
  • Endometriosis Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2024 (E)
  • TABLE 29: France Recent Past, Current & Future Analysis for Endometriosis Drugs by Product Type - Hormone therapy and Analgesics - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 30: France Historic Review for Endometriosis Drugs by Product Type - Hormone therapy and Analgesics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 31: France 16-Year Perspective for Endometriosis Drugs by Product Type - Percentage Breakdown of Value Sales for Hormone therapy and Analgesics for the Years 2014, 2024 & 2030
• GERMANY
  • Endometriosis Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2024 (E)
  • TABLE 32: Germany Recent Past, Current & Future Analysis for Endometriosis Drugs by Product Type - Hormone therapy and Analgesics - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 33: Germany Historic Review for Endometriosis Drugs by Product Type - Hormone therapy and Analgesics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 34: Germany 16-Year Perspective for Endometriosis Drugs by Product Type - Percentage Breakdown of Value Sales for Hormone therapy and Analgesics for the Years 2014, 2024 & 2030
• ITALY
  • TABLE 35: Italy Recent Past, Current & Future Analysis for Endometriosis Drugs by Product Type - Hormone therapy and Analgesics - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 36: Italy Historic Review for Endometriosis Drugs by Product Type - Hormone therapy and Analgesics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 37: Italy 16-Year Perspective for Endometriosis Drugs by Product Type - Percentage Breakdown of Value Sales for Hormone therapy and Analgesics for the Years 2014, 2024 & 2030
• UNITED KINGDOM
  • Endometriosis Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2024 (E)
  • TABLE 38: UK Recent Past, Current & Future Analysis for Endometriosis Drugs by Product Type - Hormone therapy and Analgesics - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 39: UK Historic Review for Endometriosis Drugs by Product Type - Hormone therapy and Analgesics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 40: UK 16-Year Perspective for Endometriosis Drugs by Product Type - Percentage Breakdown of Value Sales for Hormone therapy and Analgesics for the Years 2014, 2024 & 2030
• REST OF EUROPE
  • TABLE 41: Rest of Europe Recent Past, Current & Future Analysis for Endometriosis Drugs by Product Type - Hormone therapy and Analgesics - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 42: Rest of Europe Historic Review for Endometriosis Drugs by Product Type - Hormone therapy and Analgesics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 43: Rest of Europe 16-Year Perspective for Endometriosis Drugs by Product Type - Percentage Breakdown of Value Sales for Hormone therapy and Analgesics for the Years 2014, 2024 & 2030
• ASIA-PACIFIC
  • Endometriosis Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2024 (E)
  • TABLE 44: Asia-Pacific Recent Past, Current & Future Analysis for Endometriosis Drugs by Product Type - Hormone therapy and Analgesics - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 45: Asia-Pacific Historic Review for Endometriosis Drugs by Product Type - Hormone therapy and Analgesics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 46: Asia-Pacific 16-Year Perspective for Endometriosis Drugs by Product Type - Percentage Breakdown of Value Sales for Hormone therapy and Analgesics for the Years 2014, 2024 & 2030
• REST OF WORLD
  • TABLE 47: Rest of World Recent Past, Current & Future Analysis for Endometriosis Drugs by Product Type - Hormone therapy and Analgesics - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 48: Rest of World Historic Review for Endometriosis Drugs by Product Type - Hormone therapy and Analgesics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 49: Rest of World 16-Year Perspective for Endometriosis Drugs by Product Type - Percentage Breakdown of Value Sales for Hormone therapy and Analgesics for the Years 2014, 2024 & 2030

IV. COMPETITION